Pre-clinical evaluation of a 3-nitro-1,2,4-triazole analogue of [18F]FMISO as hypoxia-selective tracer for PET

Romain Bejot, Veerle Kersemans, Catherine Kelly, Laurence Carroll, Robert C. King, Véronique Gouverneur

Research output: Contribution to journalArticle

Abstract

Hypoxia in solid tumours is associated with the promotion of various metabolic mechanisms and induces resistance to radio- and chemotherapy. Non-invasive positron emission tomography (PET) or single photon emission computed tomography by use of selective biomarkers has emerged as valuable tools for the detection of hypoxic areas within tumours so treatment can be modified accordingly. The aim of this investigation was to evaluate [18F]3-NTR, a 3-nitro-1,2,4-triazole analogue (N1 substituted) of [18F]FMISO as a potential hypoxia selective tracer.3-NTR and its 18F-radiolabelled isotopic isomer were synthesised and compared with FMISO in vitro and in vivo. Their physicochemical properties were measured, the enzymatic reduction was evaluated, and the reactivity of their metabolites was investigated. Biodistribution and PET scans were performed on CBA mice bearing hypoxic CaNT tumour cells, using 18F-labelled versions of the tracers.[18F]3-NTR uptake within hypoxic cells was lower than [18F]FMISO and [18F]3-NTR did not exhibit any better selectivity than FMISO as a PET tracer in vivo. Both 18F-radiolabelled compounds are relatively evenly distributed within the whole body and the radioactive uptake within hypoxic tumours reaches a maximum at 30 min post injection and decreases thereafter. Xanthine oxidase exhibited a nitroreductase activity toward 3-NTR under anaerobic conditions, but reduced metabolites did not bind covalently.It is confirmed that 3-NTR is an electron acceptor. It is postulated that radiolabelled metabolites and fragments of [18F]3-NTR are freely diffusing due to their poor binding capacities. Thus [18F]3-NTR cannot be used as a hypoxia selective tracer for PET. The investigation provides insights into the importance of the propensity to form covalent adducts for such biomarkers.

Original languageEnglish (US)
Pages (from-to)565-575
Number of pages11
JournalNuclear Medicine and Biology
Volume37
Issue number5
DOIs
StatePublished - Jul 1 2010
Externally publishedYes

Fingerprint

Positron-Emission Tomography
Neoplasms
Biomarkers
Nitroreductases
Inbred CBA Mouse
Xanthine Oxidase
Hypoxia
1-methyl-3-nitro-1,2,4-triazole
fluoromisonidazole
1,2,4-triazole
Single-Photon Emission-Computed Tomography
Radiotherapy
Electrons
Drug Therapy
Injections

Keywords

  • [F]FMISO
  • Biomarker
  • Hypoxia
  • PET
  • Triazole
  • Tumour

ASJC Scopus subject areas

  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Pre-clinical evaluation of a 3-nitro-1,2,4-triazole analogue of [18F]FMISO as hypoxia-selective tracer for PET. / Bejot, Romain; Kersemans, Veerle; Kelly, Catherine; Carroll, Laurence; King, Robert C.; Gouverneur, Véronique.

In: Nuclear Medicine and Biology, Vol. 37, No. 5, 01.07.2010, p. 565-575.

Research output: Contribution to journalArticle

Bejot, Romain ; Kersemans, Veerle ; Kelly, Catherine ; Carroll, Laurence ; King, Robert C. ; Gouverneur, Véronique. / Pre-clinical evaluation of a 3-nitro-1,2,4-triazole analogue of [18F]FMISO as hypoxia-selective tracer for PET. In: Nuclear Medicine and Biology. 2010 ; Vol. 37, No. 5. pp. 565-575.
@article{2ee624596ca24cc1a39b8db7ce659db7,
title = "Pre-clinical evaluation of a 3-nitro-1,2,4-triazole analogue of [18F]FMISO as hypoxia-selective tracer for PET",
abstract = "Hypoxia in solid tumours is associated with the promotion of various metabolic mechanisms and induces resistance to radio- and chemotherapy. Non-invasive positron emission tomography (PET) or single photon emission computed tomography by use of selective biomarkers has emerged as valuable tools for the detection of hypoxic areas within tumours so treatment can be modified accordingly. The aim of this investigation was to evaluate [18F]3-NTR, a 3-nitro-1,2,4-triazole analogue (N1 substituted) of [18F]FMISO as a potential hypoxia selective tracer.3-NTR and its 18F-radiolabelled isotopic isomer were synthesised and compared with FMISO in vitro and in vivo. Their physicochemical properties were measured, the enzymatic reduction was evaluated, and the reactivity of their metabolites was investigated. Biodistribution and PET scans were performed on CBA mice bearing hypoxic CaNT tumour cells, using 18F-labelled versions of the tracers.[18F]3-NTR uptake within hypoxic cells was lower than [18F]FMISO and [18F]3-NTR did not exhibit any better selectivity than FMISO as a PET tracer in vivo. Both 18F-radiolabelled compounds are relatively evenly distributed within the whole body and the radioactive uptake within hypoxic tumours reaches a maximum at 30 min post injection and decreases thereafter. Xanthine oxidase exhibited a nitroreductase activity toward 3-NTR under anaerobic conditions, but reduced metabolites did not bind covalently.It is confirmed that 3-NTR is an electron acceptor. It is postulated that radiolabelled metabolites and fragments of [18F]3-NTR are freely diffusing due to their poor binding capacities. Thus [18F]3-NTR cannot be used as a hypoxia selective tracer for PET. The investigation provides insights into the importance of the propensity to form covalent adducts for such biomarkers.",
keywords = "[F]FMISO, Biomarker, Hypoxia, PET, Triazole, Tumour",
author = "Romain Bejot and Veerle Kersemans and Catherine Kelly and Laurence Carroll and King, {Robert C.} and V{\'e}ronique Gouverneur",
year = "2010",
month = "7",
day = "1",
doi = "10.1016/j.nucmedbio.2010.03.011",
language = "English (US)",
volume = "37",
pages = "565--575",
journal = "Nuclear Medicine and Biology",
issn = "0969-8051",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Pre-clinical evaluation of a 3-nitro-1,2,4-triazole analogue of [18F]FMISO as hypoxia-selective tracer for PET

AU - Bejot, Romain

AU - Kersemans, Veerle

AU - Kelly, Catherine

AU - Carroll, Laurence

AU - King, Robert C.

AU - Gouverneur, Véronique

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Hypoxia in solid tumours is associated with the promotion of various metabolic mechanisms and induces resistance to radio- and chemotherapy. Non-invasive positron emission tomography (PET) or single photon emission computed tomography by use of selective biomarkers has emerged as valuable tools for the detection of hypoxic areas within tumours so treatment can be modified accordingly. The aim of this investigation was to evaluate [18F]3-NTR, a 3-nitro-1,2,4-triazole analogue (N1 substituted) of [18F]FMISO as a potential hypoxia selective tracer.3-NTR and its 18F-radiolabelled isotopic isomer were synthesised and compared with FMISO in vitro and in vivo. Their physicochemical properties were measured, the enzymatic reduction was evaluated, and the reactivity of their metabolites was investigated. Biodistribution and PET scans were performed on CBA mice bearing hypoxic CaNT tumour cells, using 18F-labelled versions of the tracers.[18F]3-NTR uptake within hypoxic cells was lower than [18F]FMISO and [18F]3-NTR did not exhibit any better selectivity than FMISO as a PET tracer in vivo. Both 18F-radiolabelled compounds are relatively evenly distributed within the whole body and the radioactive uptake within hypoxic tumours reaches a maximum at 30 min post injection and decreases thereafter. Xanthine oxidase exhibited a nitroreductase activity toward 3-NTR under anaerobic conditions, but reduced metabolites did not bind covalently.It is confirmed that 3-NTR is an electron acceptor. It is postulated that radiolabelled metabolites and fragments of [18F]3-NTR are freely diffusing due to their poor binding capacities. Thus [18F]3-NTR cannot be used as a hypoxia selective tracer for PET. The investigation provides insights into the importance of the propensity to form covalent adducts for such biomarkers.

AB - Hypoxia in solid tumours is associated with the promotion of various metabolic mechanisms and induces resistance to radio- and chemotherapy. Non-invasive positron emission tomography (PET) or single photon emission computed tomography by use of selective biomarkers has emerged as valuable tools for the detection of hypoxic areas within tumours so treatment can be modified accordingly. The aim of this investigation was to evaluate [18F]3-NTR, a 3-nitro-1,2,4-triazole analogue (N1 substituted) of [18F]FMISO as a potential hypoxia selective tracer.3-NTR and its 18F-radiolabelled isotopic isomer were synthesised and compared with FMISO in vitro and in vivo. Their physicochemical properties were measured, the enzymatic reduction was evaluated, and the reactivity of their metabolites was investigated. Biodistribution and PET scans were performed on CBA mice bearing hypoxic CaNT tumour cells, using 18F-labelled versions of the tracers.[18F]3-NTR uptake within hypoxic cells was lower than [18F]FMISO and [18F]3-NTR did not exhibit any better selectivity than FMISO as a PET tracer in vivo. Both 18F-radiolabelled compounds are relatively evenly distributed within the whole body and the radioactive uptake within hypoxic tumours reaches a maximum at 30 min post injection and decreases thereafter. Xanthine oxidase exhibited a nitroreductase activity toward 3-NTR under anaerobic conditions, but reduced metabolites did not bind covalently.It is confirmed that 3-NTR is an electron acceptor. It is postulated that radiolabelled metabolites and fragments of [18F]3-NTR are freely diffusing due to their poor binding capacities. Thus [18F]3-NTR cannot be used as a hypoxia selective tracer for PET. The investigation provides insights into the importance of the propensity to form covalent adducts for such biomarkers.

KW - [F]FMISO

KW - Biomarker

KW - Hypoxia

KW - PET

KW - Triazole

KW - Tumour

UR - http://www.scopus.com/inward/record.url?scp=77953809615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953809615&partnerID=8YFLogxK

U2 - 10.1016/j.nucmedbio.2010.03.011

DO - 10.1016/j.nucmedbio.2010.03.011

M3 - Article

C2 - 20610161

AN - SCOPUS:77953809615

VL - 37

SP - 565

EP - 575

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

IS - 5

ER -